Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.

Patel, Atul; Agarwal, Ritesh; Rudramurthy, Shivaprakash M; Shevkani, Manoj; Xess, Immaculata; Sharma, Ratna; Savio, Jayanthi; Sethuraman, Nandini; Madan, Surabhi; Shastri, Prakash; Thangaraju, Deepak; Marak, Rungmei; Tadepalli, Karuna; Savaj, Pratik; Sunavala, Ayesha; Gupta, Neha; Singhal, Tanu; Muthu, Valliappan; Chakrabarti, Arunaloke

Patel, Atul; Agarwal, Ritesh; Rudramurthy, Shivaprakash M; Shevkani, Manoj; Xess, Immaculata; Sharma, Ratna; Savio, Jayanthi; Sethuraman, Nandini; Madan, Surabhi; Shastri, Prakash; Thangaraju, Deepak; Marak, Rungmei; Tadepalli, Karuna; Savaj, Pratik; Sunavala, Ayesha; Gupta, Neha; Singhal, Tanu; Muthu, Valliappan; Chakrabarti, Arunaloke.

Emerg Infect Dis ; 27(9): 2349-2359, 2021 Sep.

Article en En | MEDLINE | ID: mdl-34087089

Asunto(s)

COVID-19; Mucormicosis; Antifúngicos/uso terapéutico; Humanos; India/epidemiología; Mucormicosis/diagnóstico; Mucormicosis/tratamiento farmacológico; Mucormicosis/epidemiología; Pandemias; Estudios Retrospectivos; SARS-CoV-2

Palabras clave

COVID-19; India; SARS; SARS-CoV-2; amphotericin; coronavirus; coronavirus disease; diabetes; epidemiology; fungi; isavuconazole; mucormycosis; posaconazole; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 / Mucormicosis Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google